Cargando…

Determinants of COVID-19 Disease Severity–Lessons from Primary and Secondary Immune Disorders including Cancer

At the beginning of the COVID-19 pandemic, patients with primary and secondary immune disorders—including patients suffering from cancer—were generally regarded as a high-risk population in terms of COVID-19 disease severity and mortality. By now, scientific evidence indicates that there is substant...

Descripción completa

Detalles Bibliográficos
Autores principales: Solimando, Antonio G., Bittrich, Max, Shahini, Endrit, Albanese, Federica, Fritz, Georg, Krebs, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218128/
https://www.ncbi.nlm.nih.gov/pubmed/37240091
http://dx.doi.org/10.3390/ijms24108746
_version_ 1785048699905245184
author Solimando, Antonio G.
Bittrich, Max
Shahini, Endrit
Albanese, Federica
Fritz, Georg
Krebs, Markus
author_facet Solimando, Antonio G.
Bittrich, Max
Shahini, Endrit
Albanese, Federica
Fritz, Georg
Krebs, Markus
author_sort Solimando, Antonio G.
collection PubMed
description At the beginning of the COVID-19 pandemic, patients with primary and secondary immune disorders—including patients suffering from cancer—were generally regarded as a high-risk population in terms of COVID-19 disease severity and mortality. By now, scientific evidence indicates that there is substantial heterogeneity regarding the vulnerability towards COVID-19 in patients with immune disorders. In this review, we aimed to summarize the current knowledge about the effect of coexistent immune disorders on COVID-19 disease severity and vaccination response. In this context, we also regarded cancer as a secondary immune disorder. While patients with hematological malignancies displayed lower seroconversion rates after vaccination in some studies, a majority of cancer patients’ risk factors for severe COVID-19 disease were either inherent (such as metastatic or progressive disease) or comparable to the general population (age, male gender and comorbidities such as kidney or liver disease). A deeper understanding is needed to better define patient subgroups at a higher risk for severe COVID-19 disease courses. At the same time, immune disorders as functional disease models offer further insights into the role of specific immune cells and cytokines when orchestrating the immune response towards SARS-CoV-2 infection. Longitudinal serological studies are urgently needed to determine the extent and the duration of SARS-CoV-2 immunity in the general population, as well as immune-compromised and oncological patients.
format Online
Article
Text
id pubmed-10218128
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102181282023-05-27 Determinants of COVID-19 Disease Severity–Lessons from Primary and Secondary Immune Disorders including Cancer Solimando, Antonio G. Bittrich, Max Shahini, Endrit Albanese, Federica Fritz, Georg Krebs, Markus Int J Mol Sci Review At the beginning of the COVID-19 pandemic, patients with primary and secondary immune disorders—including patients suffering from cancer—were generally regarded as a high-risk population in terms of COVID-19 disease severity and mortality. By now, scientific evidence indicates that there is substantial heterogeneity regarding the vulnerability towards COVID-19 in patients with immune disorders. In this review, we aimed to summarize the current knowledge about the effect of coexistent immune disorders on COVID-19 disease severity and vaccination response. In this context, we also regarded cancer as a secondary immune disorder. While patients with hematological malignancies displayed lower seroconversion rates after vaccination in some studies, a majority of cancer patients’ risk factors for severe COVID-19 disease were either inherent (such as metastatic or progressive disease) or comparable to the general population (age, male gender and comorbidities such as kidney or liver disease). A deeper understanding is needed to better define patient subgroups at a higher risk for severe COVID-19 disease courses. At the same time, immune disorders as functional disease models offer further insights into the role of specific immune cells and cytokines when orchestrating the immune response towards SARS-CoV-2 infection. Longitudinal serological studies are urgently needed to determine the extent and the duration of SARS-CoV-2 immunity in the general population, as well as immune-compromised and oncological patients. MDPI 2023-05-14 /pmc/articles/PMC10218128/ /pubmed/37240091 http://dx.doi.org/10.3390/ijms24108746 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Solimando, Antonio G.
Bittrich, Max
Shahini, Endrit
Albanese, Federica
Fritz, Georg
Krebs, Markus
Determinants of COVID-19 Disease Severity–Lessons from Primary and Secondary Immune Disorders including Cancer
title Determinants of COVID-19 Disease Severity–Lessons from Primary and Secondary Immune Disorders including Cancer
title_full Determinants of COVID-19 Disease Severity–Lessons from Primary and Secondary Immune Disorders including Cancer
title_fullStr Determinants of COVID-19 Disease Severity–Lessons from Primary and Secondary Immune Disorders including Cancer
title_full_unstemmed Determinants of COVID-19 Disease Severity–Lessons from Primary and Secondary Immune Disorders including Cancer
title_short Determinants of COVID-19 Disease Severity–Lessons from Primary and Secondary Immune Disorders including Cancer
title_sort determinants of covid-19 disease severity–lessons from primary and secondary immune disorders including cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218128/
https://www.ncbi.nlm.nih.gov/pubmed/37240091
http://dx.doi.org/10.3390/ijms24108746
work_keys_str_mv AT solimandoantoniog determinantsofcovid19diseaseseveritylessonsfromprimaryandsecondaryimmunedisordersincludingcancer
AT bittrichmax determinantsofcovid19diseaseseveritylessonsfromprimaryandsecondaryimmunedisordersincludingcancer
AT shahiniendrit determinantsofcovid19diseaseseveritylessonsfromprimaryandsecondaryimmunedisordersincludingcancer
AT albanesefederica determinantsofcovid19diseaseseveritylessonsfromprimaryandsecondaryimmunedisordersincludingcancer
AT fritzgeorg determinantsofcovid19diseaseseveritylessonsfromprimaryandsecondaryimmunedisordersincludingcancer
AT krebsmarkus determinantsofcovid19diseaseseveritylessonsfromprimaryandsecondaryimmunedisordersincludingcancer